Results 81 to 90 of about 29,923 (224)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, restores blood–brain barrier integrity in a human stem cell‐based model of ischaemic stroke

British Journal of Pharmacology, EarlyView.
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó, Koppány Párdi, Zuhao Cui, Gergő Porkoláb, Zsófia Hoyk, Csilla Kovács, Janet F. Adegbite, Virág Fodor, Nárcisz M. Cser, László Dér, Krisztina Nagy, Csilla Sajben, Roland Tengölics, Mária A. Deli, Szilvia Veszelka   +14 more
wiley   +1 more source

Somatostatin receptors in the thymus.

Annals of medicine, 1999
The thymus is the primary lymphoid organ where different factors participate in regulating the proliferation and differentiation of T cells. The thymic epithelium is the main cellular component in driving the maturation of thymocytes through cell-to-cell and extracellular matrix-mediated interactions.
D. Ferone, P. M. van Hagen, COLAO, ANNAMARIA, ANNUNZIATO, LUCIO, S. W. Lamberts, L. J. Hofland   +5 more
openaire   +4 more sources

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source

Characterization of the somatostatin system in tilapia: implications for growth and reproduction

Frontiers in Endocrinology
Somatostatin (SST) plays diverse physiological roles in vertebrates, particularly in regulating growth hormone secretion from the pituitary. While the function of SST as a neuromodulator has been studied extensively, its role in fish and mammalian ...
Naama Mizrahi, Lian Hollander-Cohen, Ishwar Atre, Miriam Shulman, Aurora Campo, Berta Levavi-Sivan   +5 more
doaj   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease. Design LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol ...
John Newell‐Price, Beverly M. K. Biller, Maria Fleseriu, Beatrice Gueron, Grzegorz Binowski, Anna Paćkowska, Mônica R. Gadelha   +6 more
wiley   +1 more source

Is Hypercortisolism Treatable? Which Patients Should Be Treated and How—A Practical Guide for Clinicians

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To provide a practical guide on when to suspect endogenous hypercortisolism, how to use the overnight 1‐mg dexamethasone suppression test (DST) for targeted case‐finding, and which patients are most likely to benefit from treatment.
Juan Pablo Frias
wiley   +1 more source

Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery

World Journal of Surgery, EarlyView.
Matilda Anneback, Priya H. Dedhia, Aimee Di Marco, Els Nieveen van Dijkum, Julie A. Miller, Janice L. Pasieka   +5 more
wiley   +1 more source